We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-0.68%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$4.76B
AUM Growth
-$304M
Cap. Flow
+$23.1M
Cap. Flow %
0.49%
Top 10 Hldgs %
26.26%
Holding
167
New
11
Increased
69
Reduced
16
Closed
14

Top Buys

Rank Stock Value
1
BAX icon
Baxter International
BAX
+$35.6M
2
WRBY icon
Warby Parker
WRBY
+$35M
3
RARE icon
Ultragenyx Pharmaceutical
RARE
+$30.4M
4
IMRX icon
Immuneering
IMRX
+$29.3M
5
ABOS icon
Acumen Pharmaceuticals
ABOS
+$26.3M

Top Sells

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$68.6M
2
ARDX icon
Ardelyx
ARDX
+$39.8M
3
BIIB icon
Biogen
BIIB
+$39.3M
4
BSX icon
Boston Scientific
BSX
+$34.2M
5
PPD
PPD, Inc. Common Stock
PPD
+$31.1M

Sector Composition

Rank Sector Weight
1 Healthcare 93.24%
2 Consumer Staples 1.58%
3 Industrials 0.82%
4 Financials 0.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGL icon
1
Agilon Health
AGL
$1.53B
$185M 3.9%
283,000
+3,039
+1% +$2.6M
HUM icon
2
Humana
HUM
$43.7B
$133M 2.8%
342,000
+39,500
+13% +$16.8M
ALGN icon
3
Align Technology
ALGN
$12.1B
$133M 2.8%
200,000
+12,250
+7% +$8.32M
PODD icon
4
Insulet
PODD
$11.5B
$124M 2.62%
437,566
+28,816
+7% +$8.22M
ISRG icon
5
Intuitive Surgical
ISRG
$127B
$119M 2.51%
360,000
– –
AGIO icon
6
Agios Pharmaceuticals
AGIO
$1.79B
$118M 2.48%
2,556,179
-18,129
-0.7% -$876K
ZLAB icon
7
Zai Lab
ZLAB
$2.06B
$114M 2.39%
1,077,750
+63,750
+6% +$9.15M
IDXX icon
8
Idexx Laboratories
IDXX
$44.1B
$112M 2.35%
180,000
– –
HCA icon
9
HCA Healthcare
HCA
$87.2B
$109M 2.3%
450,000
– –
NBIX icon
10
Neurocrine Biosciences
NBIX
$16.8B
$101M 2.12%
1,051,500
+36,500
+4% +$3.45M
ARGX icon
11
argenx
ARGX
$53.4B
$95.1M 2%
315,000
– –
NVAX icon
12
Novavax
NVAX
$1.2B
$94.3M 1.98%
455,000
– –
UNH icon
13
UnitedHealth
UNH
$376B
$93.8M 1.97%
240,000
– –
IMCR icon
14
Immunocore
IMCR
$1.72B
$90.6M 1.91%
2,445,155
+50,370
+2% +$1.7M
BPMC
15
DELISTED
Blueprint Medicines
BPMC
$87.4M 1.84%
849,659
+40,799
+5% +$3.8M
HZNP
16
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$76.9M 1.62%
702,000
+77,000
+12% +$7.99M
FRPT icon
17
Freshpet
FRPT
$2.93B
$75.2M 1.58%
527,000
+20,500
+4% +$2.93M
NVTA
18
DELISTED
Invitae Corporation
NVTA
$74.1M 1.56%
2,605,829
+303,797
+13% +$8.9M
NVRO
19
DELISTED
NEVRO CORP.
NVRO
$74M 1.56%
635,700
+104,700
+20% +$13.7M
RARE icon
20
Ultragenyx Pharmaceutical
RARE
$2.45B
$72.3M 1.52%
801,109
+336,109
+72% +$30.4M
ACRS icon
21
Aclaris Therapeutics
ACRS
$726M
$68.5M 1.44%
3,803,232
+40,920
+1% +$656K
EW icon
22
Edwards Lifesciences
EW
$49.6B
$65.9M 1.39%
582,000
– –
ASND icon
23
Ascendis Pharma A/S
ASND
$16B
$63.8M 1.34%
400,000
+166,500
+71% +$22.8M
MRTX
24
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$62.5M 1.32%
353,514
+34,429
+11% +$5.54M
PHR icon
25
Phreesia
PHR
$663M
$59.8M 1.26%
970,000
+10,000
+1% +$667K
1
2 3 4 5

Similar funds

AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
SGI
Summit Global Investments Bountiful, Utah $1.69B AUM 12.13% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return

Rock Springs Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, Rock Springs Capital Management held 167 positions worth $4.76B, down 6% from $5.06B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Rock Springs Capital Management's Q3 2021 filing shows 11 new, 69 increased, 16 reduced and 14 closed positions. Its largest new stake was Baxter International: 450,000 shares worth $36.2M. The largest sale was BeOne Medicines Ltd, an estimated $68.6M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 94% a quarter earlier, followed by Consumer Staples and Industrials.

  • Rock Springs Capital Management's largest Q3 2021 buy was Baxter International: 450,000 shares worth $36.2M.
  • Rock Springs Capital Management added most to Ultragenyx Pharmaceutical in Q3 2021, an estimated $30.4M increase.
  • Rock Springs Capital Management's biggest Q3 2021 reduction was Prothena Corp, cutting an estimated $14.9M.
  • Rock Springs Capital Management fully exited BeOne Medicines Ltd in Q3 2021, selling an estimated $68.6M.
  • Rock Springs Capital Management's ten largest holdings make up 26% of its $4.76B portfolio in Q3 2021.
  • Rock Springs Capital Management opened 11 new positions and closed 14 in Q3 2021.
  • Rock Springs Capital Management's portfolio value fell 6% quarter-over-quarter to $4.76B.

Based on Rock Springs Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.